More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indicat

Mar 12, 2021

10 likes | 12 Views

The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon enter the market.<br><br>To order this 330 page report, which features 130 figures and 145 tables, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html<br>

kevin987

Download Presentation

More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indicat

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D